US 12,447,210 B2
Pharmaceutical composition comprising anti-human TSLP receptor antibody
Megumi Ikeda, Chuo-ku (JP); and Akinori Chikushi, Chuo-ku (JP)
Assigned to Upstream Bio, Inc., Waltham, MA (US)
Filed by UPSTREAM BIO, INC., Waltham, MA (US)
Filed on Jun. 8, 2023, as Appl. No. 18/331,422.
Application 18/331,422 is a continuation of application No. 17/172,490, filed on Feb. 10, 2021, granted, now 11,712,472.
Application 17/172,490 is a continuation of application No. 16/063,124, granted, now 10,994,011, issued on May 4, 2021, previously published as PCT/JP2016/087480, filed on Dec. 16, 2016.
Claims priority of application No. 2015-246826 (JP), filed on Dec. 18, 2015.
Prior Publication US 2023/0398213 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/39591 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); C07K 16/24 (2013.01); C07K 16/2866 (2013.01); A61K 9/19 (2013.01); C07K 2317/21 (2013.01)] 22 Claims
 
1. A pharmaceutical composition with a pH of about 5 to about 6 comprising: an anti-human TSLP receptor antibody, or an antigen-binding fragment thereof, at a concentration of 1 mg/mL to 300 mg/mL;
a pharmaceutically acceptable buffer at a concentration of 5 to 100 mmol/L;
a stabilizer; and
a surfactant present in an amount of 0.001 to 1% (w/v),
wherein the anti-human TSLP receptor antibody, or an antigen-binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 1 with a posttranslational modification, and a light chain having the amino acid sequence of SEQ ID NO: 3, and wherein the posttranslational modification of the heavy chain is a lysine deletion at the C terminus of the heavy chain having the amino acid sequence of SEQ ID NO: 1, or a pyroglutamylation at the N-terminus of the heavy chain having the amino acid sequence of SEQ ID NO: 1.